TY  - JOUR
TI  - Evaluation of COVID-19 clinical features and outcomes in individuals with rheumatic disease
AB  - Purpose: The aim of this study was to evaluate the clinical features and course of coronavirus disease 2019 (COVID- 19) in individuals with rheumatic disease. Materials and Methods: This retrospective study was carried out at the Erciyes University rheumatology outpatient clinic from July 1 to August 1, 2021. The demographic and clinical data and summarized COVID- 19 history, clinical course of COVID-19, fatigue, and pain levels of patients with rheumatic disease were obtained from our institutional electronic registration database and patient files. Results: Recruited participants were 106 individuals (83% female, %17 male) with rheumatic disease who had been confirmed by laboratory tests to have COVID-19 and recovered from the COVID-19 infection. Their mean age and body mass index (BMI) were 48.69±11.5 years and 29.89±6.76 kg/m2, respectively. Additionally, 21 (19.8%) had been hospitalized, and five (4.7%) had been admitted to the intensive care unit. The most common rheumatic diseases were axial spondyloarthritis (40; 37.7%) and rheumatoid arthritis (26 cases; 24.5%). Patients who received conventional synthetic disease-modifying drugs (csDMARDs) reportedly experienced more pain, fatigue, and headaches than those in the biologic agent and non- steroidal anti-inflammatory drug (NSAID) groups. Conclusion: Our study results reveal similar symptoms and hospitalization rates among patients with rheumatic disease who recovered from COVID-19 and received either csDMARDs, biologic agents, or NSAIDs. However, patients in the csDMARD group reported more pain, fatigue, and headache compared to the other groups.
AU  - Sas, Senem
AU  - cengiz, gizem
DO  - 10.17826/cumj.1097052
PY  - 2022
JO  - Cukurova Medical Journal
VL  - 47
IS  - 4
SN  - 2602-3032
SP  - 1431
EP  - 1439
DB  - TRDizin
UR  - http://search/yayin/detay/1149660
ER  -